Cargando…

Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β(1)-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients

BACKGROUND: β-Adrenoceptor antagonists (β-blockers) have been reported to be effective for regulation of heart rate (HR) and restoring sinus rhythm in postoperative atrial fibrillation and atrial flutter, as well as in the prevention of those arrhythmias after open-heart surgery. OBJECTIVES: The obj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taenaka, Nobuyuki, Kikawa, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing AG 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691491/ https://www.ncbi.nlm.nih.gov/pubmed/23728899 http://dx.doi.org/10.1007/s40261-013-0093-x

Ejemplares similares

The Effectiveness and Safety of Landiolol Hydrochloride, an Ultra-Short-Acting β(1)-Blocker, in Postoperative Patients with Supraventricular Tachyarrhythmias: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Taenaka, Nobuyuki, et al.
Publicado: (2013)

Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction
por: Wada, Yuko, et al.
Publicado: (2016)

Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia
por: Kiuchi, Shunsuke, et al.
Publicado: (2017)

Dose-dependent scavenging activity of the ultra-short-acting β1-blocker landiolol against specific free radicals
por: Matsumoto, Shigekiyo, et al.
Publicado: (2022)

Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies
por: Ashida, Atsuko, et al.
Publicado: (2021)

Landiolol for refractory tachyarrhythmias in the intensive care unit: case reports
por: Gangl, Clemens, et al.
Publicado: (2022)

Characteristic interactivity of landiolol, an ultra-short-acting highly selective β(1)-blocker, with biomimetic membranes: Comparisons with β(1)-selective esmolol and non-selective propranolol and alprenolol
por: Tsuchiya, Hironori, et al.
Publicado: (2013)

Dose-Finding Study of Landiolol Hydrochloride: A Short-Acting β(1)-Blocker for Controlling Heart Rate During Coronary Computed-Tomography Angiography in Japan
por: Hirano, Masaharu, et al.
Publicado: (2013)

Outcome of catheter ablation of supraventricular tachyarrhythmias in cardiac sarcoidosis
por: Willy, Kevin, et al.
Publicado: (2019)

Hypocalcemia: A Little Known Cause of Supraventricular Tachyarrhythmia
por: Khalid, Sualeha, et al.
Publicado: (2023)

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients
por: Yamamoto, Haruko, et al.
Publicado: (2019)

Effect of landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series
por: Ditali, Valentina, et al.
Publicado: (2021)

A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β(1)-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease
por: Jinzaki, Masahiro, et al.
Publicado: (2013)

Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias
por: Schupp, Tobias, et al.
Publicado: (2022)

The effect of telmisartan on the ventricular systolic function in dogs with experimental supraventricular tachyarrhythmia
por: KAWAGUCHI, Takae, et al.
Publicado: (2019)

Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure
por: Shiga, Tsuyoshi
Publicado: (2022)

The application of catheter ablation in a rare case with coughing‐induced supraventricular tachyarrhythmias
por: Wang, Xin‐hua, et al.
Publicado: (2017)

Efficacy and Safety of Landiolol in Patients With Ventricular Tachyarrhythmias With or Without Renal Impairment　― Subanalysis of the J-Land II Study ―
por: Shiga, Tsuyoshi, et al.
Publicado: (2020)

Efficacy and safety of cardioversion with continuous landiolol infusion for atrial tachyarrhythmia in an inflammatory state caused by volvulus in a child with TARP syndrome and postoperative tetralogy of Fallot
por: Miyamoto, Kenji, et al.
Publicado: (2018)

The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature
por: Bezati, Sofia, et al.
Publicado: (2022)

Is amiodarone a safe antiarrhythmic to use in supraventricular tachyarrhythmias after lung cancer surgery?
por: Barbetakis, Nikolaos, et al.
Publicado: (2004)

A case of ultrashort‐acting beta‐blocker landiolol hydrochloride for takotsubo syndrome with left ventricular outflow tract obstruction
por: Takama, Takuro, et al.
Publicado: (2018)

Preventive effect of low-dose landiolol on postoperative atrial fibrillation study (PELTA study)
por: Sasaki, Konosuke, et al.
Publicado: (2020)

Effects of Intravenous Landiolol on Heart Rate and Outcomes in Patients with Atrial Tachyarrhythmias and Acute Decompensated Heart Failure: A Single-Center Experience
por: Matsui, Yuko, et al.
Publicado: (2019)

Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study
por: Matsuda, Naoyuki, et al.
Publicado: (2020)

Use of contrast-enhanced MRI of the heart in detection of risk of supraventricular tachyarrhythmias in patients with recent myocardial infarction
por: Mochula, Olga, et al.
Publicado: (2015)

Evaluation of medical and psychological parameters of quality of life in supraventricular tachyarrhythmia children. A comparison with healthy children
por: Szafran, Emilia, et al.
Publicado: (2016)

Multiple antiarrhythmic transplacental treatments for fetal supraventricular tachyarrhythmia: A protocol for systematic review and meta analysis
por: Chen, Tingting, et al.
Publicado: (2020)

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Short-Acting β(1)-Adrenergic Receptor Blocker Landiolol Hydrochloride for Coronary Computed Tomography Angiography in Japanese Patients with Suspected Ischemic Cardiac Disease
por: Hirano, Masaharu, et al.
Publicado: (2013)

Landiolol, an intravenous β1‐selective blocker, is useful for dissociating a fusion of atrial activation via accessory pathway and atrioventricular node
por: Kinjo, Takahiko, et al.
Publicado: (2023)

Direct effects of esmolol, ultra-short-acting β-blockers, on cardiac function, ion channels, and coronary arteries in guinea pigs
por: Shibata, S
Publicado: (2011)

Atrial Electrography for Postoperative Tachyarrhythmia Analysis in Patients
por: Peotter, Ashley M., et al.
Publicado: (2021)

Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias
por: Schupp, Tobias, et al.
Publicado: (2022)

Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis
por: Hao, Jianqi, et al.
Publicado: (2021)

Safety and effective use of landiolol in the ICU
por: Hifumi, Toru, et al.
Publicado: (2014)

Catheter ablation for ventricular tachyarrhythmia in patients with channelopathies
por: Murakoshi, Nobuyuki, et al.
Publicado: (2016)

Perioperative Administration of an Intravenous Beta-Blocker Landiolol Hydrochloride in Patients with Lung Cancer: A Japanese Retrospective Exploratory Clinical Study
por: Sakamoto, Atsuhiro, et al.
Publicado: (2019)

Study of hemodynamics in patients treated with landiolol in the ICU
por: Imabayashi, T, et al.
Publicado: (2009)

Landiolol for managing atrial fibrillation in intensive care
por: Rehberg, Sebastian, et al.
Publicado: (2018)

Landiolol for managing post-operative atrial fibrillation
por: Balik, Martin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o30urt63nddromnskq46q10av9